Zidovudine is used to treat human immunodeficiency virus (HIV) infection and for the prevention of transmitting HIV from infected mother to infant during labor and delivery. Zidovudine, a structural analog of thymidine, is phosphorylated intracellularly by cellular thymidine kinase to zidovudine monophosphate. The monophosphate is converted to the diphosphate by cellular thymidylate kinase and is further converted to the triphosphate by other cellular enzymes. Zidovudine triphosphate competes with the natural substrate, thymidine triphosphate, for incorporation into growing chains of viral RNA-dependent DNA polymerase (reverse transcriptase), thereby inhibiting viral DNA replication. Once incorporated, zidovudine triphosphate also prematurely terminates the growing DNA chain since the 3′-azido group prevents further 5′ to 3′ phosphodiester linkages. Zidovudine has a 100- to 300-fold greater affinity for inhibiting HIV reverse transcriptase than it does for inhibiting human DNA polymerase.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Zidovudine, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.